1. Pseudoprogression Is Frequent After Front-Line Radiation Therapy in Pediatric Low-Grade Glioma : Results From the German Low-Grade Glioma Cohort
- Author
-
Annika Stock, Caroline-Viktoria Hancken, Daniela Kandels, Rolf-Dieter Kortmann, Stefan Dietzsch, Beate Timmermann, Torsten Pietsch, Brigitte Bison, Rene Schmidt, Mirko Pham, Astrid Katharina Gnekow, and Monika Warmuth-Metz
- Subjects
Male ,Cancer Research ,Radiation ,Brain Neoplasms ,Medizin ,Glioma ,Magnetic Resonance Imaging ,Oncology ,Disease Progression ,Proton Therapy ,Humans ,Female ,Radiology, Nuclear Medicine and imaging ,Child - Abstract
Expansion of magnetic resonance imaging T2- or T1-tumor lesion volume after radiation therapy (RT) may indicate pseudoprogression (PsPD). The differentiation between true progression and PsPD is a clinical challenge and underinvestigated in pediatric low-grade glioma (LGG). We evaluated radiologic criteria for PsPD after front-line RT and investigated the frequency and duration of PsPD after 3 RT-modalities within the framework of the German pediatric multicenter LGG-studies.Baseline and follow-up magnetic resonance imaging scans of 136 patients (72 male [52.9%], median age at start of RT of 11.3 years [range, 0.8-25.9]) of the Society for Pediatric Oncology-LGG 2004 study and LGG-registry cohorts (Definite PsPD was radiologically determined in 54 of 136 (39.7%) without differences in frequency between RT-modalities: IS 22 of 48 versus XRT 24 of 54 versus PBT 11 of 20; P = .780. Definite PsPD occurred at median 6.3 months (IS 7.2 months; XRT 4.4 months; PBT 6.5 months) after RT-initiation and persisted for median 7.2 months (IS 8.5 months; XRT 7 months; PBT 7.4 months). Appearance of necrosis within the focal tumor-associated T2 lesion proved to be a relevant associated predictor of definite PsPD (P.001).PsPD is frequent after irradiation of pediatric LGG and independent of the RT modality (IS vs XRT vs PBT). Adequate identification of PsPD versus true progression is imperative to prevent unneeded salvage treatment.
- Published
- 2022